What are the NCCN guidelines for second-line therapy for mantle cell lymphoma (MCL)?

Updated: Mar 15, 2019
  • Author: Muhammad Rashid Abbasi, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Answer

Second-line therapy regimens are as follows:

  • Bendamustine ± rituximab
  • Bendamustine, bortezomib, and rituximab (category 2B)
  • Bortezomib ± rituximab
  • Cladribine + rituximab
  • FC (fludarabine, cyclophosphamide) ± rituximab (category 3)
  • Ibrutinib
  • Ibrutinib, lenalidomide, rituximab (category 2B)
  • Lenalidomide ± rituximab
  • PCR (pentostatin, cyclophosphamide, rituximab) (category 3)
  • PEPC (prednisone, etoposide, procarbazine, cyclophosphamide) ± rituximab (category 3)
  • Venetoclax

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!